AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8332152 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment (ceftriaxone as directed by physicians)
Number of subjects: 86
Study 8332152 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 86
Study 8332152 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 86
Study 8332152 — intervention group
Group type: COMPARATOR
Intervention: Higher-risk children treated as inpatients
Number of subjects: 86
Study 3793953 — intervention group
Group type: COMPARATOR
Intervention: Chlorpropamide (C) alone
Number of subjects: 12
Study 3793953 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide (C) with sucralfate (S)
Number of subjects: 12
Study 30882476 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 (colloid)
Number of subjects: 1057
Study 30882476 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (crystalloid)
Number of subjects: 1057
Study 27129476 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting in 2 Worlds (P2W)
Number of subjects: 575
Study 27129476 — intervention group
Group type: COMPARATOR
Intervention: Healthy Families in 2 Worlds (HF2W)
Number of subjects: 575
Study 25155227 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 600
Study 22244349 — intervention group
Group type: EXPERIMENTAL
Intervention: MMN-1
Number of subjects: 324
Study 22244349 — intervention group
Group type: EXPERIMENTAL
Intervention: MMN-2
Number of subjects: 324
Study 22244349 — intervention group
Group type: COMPARATOR
Intervention: IFA-2
Number of subjects: 324
Study 22244349 — intervention group
Group type: EXPERIMENTAL
Intervention: MMN-1 and MMN-2
Number of subjects: 324
Study 21246578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish treatment
Number of subjects: 20
Study 21246578 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated surfaces)
Number of subjects: 20
Study 17349686 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ATCC 55730 (1 x 10(8) colony forming units) daily from gestational week 36 until delivery and continued from birth until 12 months of age.
Number of subjects: 188
Study 17349686 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (not specified dosage or duration).
Number of subjects: 188
Study 17349686 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri group.
Number of subjects: 188
Study 17349686 — intervention group
Group type: COMPARATOR
Intervention: Placebo group.
Number of subjects: 188
Study 16248382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic scans of thallium-201 (201Tl) scintigraphy
Number of subjects: 175
Study 12960597 — intervention group
Group type: EXPERIMENTAL
Intervention: 201Tl‐chloride scintigraphy (early image)
Number of subjects: 21
Study 12960597 — intervention group
Group type: EXPERIMENTAL
Intervention: 201Tl‐chloride scintigraphy (delayed image)
Number of subjects: 21
Study 12960597 — intervention group
Group type: COMPARATOR
Intervention: Bone scintigraphy
Number of subjects: 21
Study 12960597 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up 201Tl‐chloride scintigraphy after chemotherapy
Number of subjects: 21
Study 10824635 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion after pretreatment with nadolol or propranolol
Number of subjects: 8
Study 10824635 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol infusion
Number of subjects: 8
Study 10824635 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol or propranolol (doses < or =40 mg)
Number of subjects: 8
Study 10824635 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (doses < or =7.5 mg)
Number of subjects: 8
Study 9238585 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-Adjusted Clinical Epidemiology (PACE) strategy
Number of subjects: 0
Study 9238585 — intervention group
Group type: COMPARATOR
Intervention: Megatrial approach
Number of subjects: 0
Study 1430708 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lysine acetylsalicylate (L‐ASA) 900 mg
Number of subjects: 13
Study 1430708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1430708 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sodium salicylate (equivalent dose)
Number of subjects: 13
Study 1430708 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled indomethacin (25 mg and 50 mg)
Number of subjects: 13
Study 6539002 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanozolol 50 mg intramuscularly 24 hr before surgery
Number of subjects: 60
Study 6539002 — intervention group
Group type: COMPARATOR
Intervention: Placebo intramuscularly
Number of subjects: 60
Study 3524929 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 240 mg orally for 12 weeks
Number of subjects: 19
Study 3524929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31337167 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage, long-duration pulsed radiofrequency (PRF) at 42°C for 900 seconds
Number of subjects: 96
Study 31337167 — intervention group
Group type: COMPARATOR
Intervention: Sham group (no radiofrequency energy output)
Number of subjects: 96
Study 31337167 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage, long-duration pulsed radiofrequency (PRF)
Number of subjects: 96
Study 29046302 — intervention group
Group type: COMPARATOR
Intervention: Tea administered simultaneously with the meal (TM-2)
Number of subjects: 12
Study 29046302 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea administered 1 hour postmeal (TM-3)
Number of subjects: 12
Study 29046302 — intervention group
Group type: COMPARATOR
Intervention: Water administered with the meal (TM-1)
Number of subjects: 12
Study 29046302 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TM-2 and TM-3
Number of subjects: 12
Study 25796146 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine combined with enalapril
Number of subjects: 114
Study 25796146 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (control group)
Number of subjects: 114
Study 24045528 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention
Number of subjects: 0
Study 24045528 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21208648 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile circular skin graft (PCG)
Number of subjects: 37
Study 21208648 — intervention group
Group type: COMPARATOR
Intervention: Penile skin flap (PCF)
Number of subjects: 37
Study 21208648 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PCG and PCF)
Number of subjects: 37
Study 19256728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 19256728 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric Music Therapy
Number of subjects: 0
Study 19256728 — intervention group
Group type: EXPERIMENTAL
Intervention: Future Music Therapy Research
Number of subjects: 0
Study 17580544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment applied on lumbar paravertebral muscle
Number of subjects: 31
Study 17580544 — intervention group
Group type: COMPARATOR
Intervention: Placebo (machine not switched on)
Number of subjects: 31
Study 17580544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment
Number of subjects: 31
Study 14694916 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (5 L/min)
Number of subjects: 33
Study 14694916 — intervention group
Group type: COMPARATOR
Intervention: Air (5 L/min)
Number of subjects: 33
Study 10869641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine (2 mg, dose-optimization schedule)
Number of subjects: 569
Study 10869641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine (5 mg, fixed-dose)
Number of subjects: 569
Study 10869641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine (6 mg, fixed-dose)
Number of subjects: 569
Study 10869641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine (all doses)
Number of subjects: 569
Study 10869641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 569
Study 9186252 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) controlled release (CR) 400 mg initial administration
Number of subjects: 0
Study 9186252 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) controlled release (CR) 400 mg twice daily for 1 month
Number of subjects: 0
Study 9186252 — intervention group
Group type: COMPARATOR
Intervention: Control group (young healthy volunteers)
Number of subjects: 0
Study 1607415 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream, applied twice daily for 1 week
Number of subjects: 159
Study 1607415 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 159
Study 4026357 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (1 mg/kg) administered intravenously at approximately 24 hour intervals for three doses.
Number of subjects: 85
Study 4026357 — intervention group
Group type: COMPARATOR
Intervention: Control group (no frusemide).
Number of subjects: 85
Study 30261471 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based prevention program (JuvenTUM 3)
Number of subjects: 434
Study 26811189 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional blocks (bilateral CNV2 and CNV3 divisions of the trigeminal nerve) with local anaesthesia containing 1/100,000 epinephrine and 10 ml 0.5% levobupivacaine.
Number of subjects: 50
Study 26811189 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional blocks (bilateral CNV2 and CNV3 divisions of the trigeminal nerve).
Number of subjects: 50
Study 26811189 — intervention group
Group type: COMPARATOR
Intervention: No regional blocks (group A).
Number of subjects: 50
Study 24305905 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support workers (PSWs) trained over 12 weekly, 1-day sessions from April to July 2010.
Number of subjects: 0
Study 24305905 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support workers (PSWs)
Number of subjects: 0
Study 24305905 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervision and support provided by a peer support coordinator and a training facilitator.
Number of subjects: 0
Study 22218245 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ofloxacin
Number of subjects: 300
Study 22218245 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Povidone Iodine (PI) instillation
Number of subjects: 300
Study 22218245 — intervention group
Group type: COMPARATOR
Intervention: Manual SICS
Number of subjects: 300
Study 22218245 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification (Phaco)
Number of subjects: 300
Study 22218245 — intervention group
Group type: COMPARATOR
Intervention: Well-controlled diabetics
Number of subjects: 300
Study 22218245 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetics
Number of subjects: 300
Study 20603858 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic placement of polypropylene mesh in the preperitoneal plane
Number of subjects: 85
Study 20603858 — intervention group
Group type: COMPARATOR
Intervention: Routine abdominal mass closure after AAA repair (Control)
Number of subjects: 85
Study 18390395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intubation (OI)
Number of subjects: 71
Study 18390395 — intervention group
Group type: COMPARATOR
Intervention: Nasal intubation (NI)
Number of subjects: 71
Study 16231265 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-day regimen of antiretroviral therapy and counseling
Number of subjects: 877
Study 12657405 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil anesthesia
Number of subjects: 40
Study 12657405 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-remifentanil anesthesia
Number of subjects: 40
Study 10410476 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane stripping
Number of subjects: 96
Study 10410476 — intervention group
Group type: COMPARATOR
Intervention: Control (no membrane stripping)
Number of subjects: 96
Study 10410476 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study 7755228 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of alcohol
Number of subjects: 10
Study 7755228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2077981 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam sedation
Number of subjects: 32
Study 2077981 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia alone
Number of subjects: 32
Study 537567 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine (p.o.)
Number of subjects: 6
Study 537567 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocin (p.o.)
Number of subjects: 6
Study 537567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (p.o.)
Number of subjects: 6
Study 537567 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine (i.v.)
Number of subjects: 6
Study 537567 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocin (i.v.)
Number of subjects: 6
Study 537567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (i.v.)
Number of subjects: 6
Study 30770639 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printing group
Number of subjects: 30
Study 30770639 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 30149668 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-informed school-based intervention consisting of ten sessions based on social cognitive theory and the social influences approach.
Number of subjects: 1279
Study 30149668 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 1279
Study 30149668 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-informed school-based intervention.
Number of subjects: 1279
Study 27352494 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint implantation at Fengchi (GB 20), Taiyang (EX‐HN 5), Waiguan (TE 5), Yanglingquan (GB 34), once every 2 weeks for 4 weeks.
Number of subjects: 60
Study 27352494 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA) at the same acupoints as the implantation group, applied once every two days for 4 weeks.
Number of subjects: 60
Study 24560764 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain radiation therapy (WBRT) after local treatment of melanoma brain metastases
Number of subjects: 77
Study 21790621 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (RBCs if Hb concentration was 70 g/L or less intraoperatively during CPB and 75 g/L or less postoperatively)
Number of subjects: 50
Study 21790621 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (RBCs if Hb concentration was 95 g/L or less during CPB and less than 100 g/L postoperatively)
Number of subjects: 50
Study 19896194 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-wavelength automated perimetry (SWAP)
Number of subjects: 416
Study 19896194 — intervention group
Group type: COMPARATOR
Intervention: Standard automated perimetry (SAP)
Number of subjects: 416
Study 17981847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (5 hours/week for 12 weeks)
Number of subjects: 121
Study 17981847 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (2 hours/week for 12 weeks)
Number of subjects: 121
Study 17981847 — intervention group
Group type: COMPARATOR
Intervention: NHS group (2 hours/week for 12 weeks)
Number of subjects: 121
Study 15222004 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/m(2) of docetaxel every 14 days with lenograstim
Number of subjects: 39
Study 15222004 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/m(2) of docetaxel every 10 days with lenograstim
Number of subjects: 39
Study 15222004 — intervention group
Group type: COMPARATOR
Intervention: 100 mg/m(2) of docetaxel every 21 days without lenograstim
Number of subjects: 39
Study 15222004 — intervention group
Group type: COMPARATOR
Intervention: 100 mg/m(2) of docetaxel every 18 days with lenograstim
Number of subjects: 39
Study 12122788 — intervention group
Group type: EXPERIMENTAL
Intervention: Creme
Number of subjects: 12
Study 12122788 — intervention group
Group type: COMPARATOR
Intervention: Powder
Number of subjects: 12
Study 9630389 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar (acetic acid) added to a starchy meal
Number of subjects: 10
Study 9630389 — intervention group
Group type: COMPARATOR
Intervention: White bread reference meal (control)
Number of subjects: 10
Study 11271340 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 49
Study 11271340 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin (CyA)
Number of subjects: 49
Study 11271340 — intervention group
Group type: COMPARATOR
Intervention: CyA
Number of subjects: 49
Study 3184026 — intervention group
Group type: EXPERIMENTAL
Intervention: COMMUNITY-based dental delivery system
Number of subjects: 725
Study 3184026 — intervention group
Group type: COMPARATOR
Intervention: SCHOOL-based dental delivery system
Number of subjects: 725
Study 3184026 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (COMMUNITY and SCHOOL)
Number of subjects: 725
Study 31596648 — intervention group
Group type: EXPERIMENTAL
Intervention: Ria Treatment Platform (RTP)
Number of subjects: 77
Study 29504187 — intervention group
Group type: EXPERIMENTAL
Intervention: AZ11760788
Number of subjects: 36
Study 29504187 — intervention group
Group type: EXPERIMENTAL
Intervention: AZ12048189
Number of subjects: 36
Study 29504187 — intervention group
Group type: EXPERIMENTAL
Intervention: AZ12099548
Number of subjects: 36
Study 27599039 — intervention group
Group type: EXPERIMENTAL
Intervention: IMM-101 (10 mg/ml intradermally) + GEM (1000 mg/m² intravenously)
Number of subjects: 110
Study 27599039 — intervention group
Group type: COMPARATOR
Intervention: GEM alone
Number of subjects: 110
Study 25409371 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nasoenteric tube feeding within 24 hours after randomization
Number of subjects: 208
Study 25409371 — intervention group
Group type: COMPARATOR
Intervention: Oral diet initiated 72 hours after presentation (on-demand group)
Number of subjects: 208
Study 25409371 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nasoenteric tube feeding
Number of subjects: 208
Study 22520136 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV (Rotarix) 2 doses (10 and 14 weeks)
Number of subjects: 1339
Study 22520136 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV (Rotarix) 3 doses (6, 10 and 14 weeks)
Number of subjects: 1339
Study 22520136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1339
Study 20656094 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy intervention
Number of subjects: 163
Study 20656094 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 163
Study 18829392 — intervention group
Group type: EXPERIMENTAL
Intervention: MLN0002 2.0 mg/kg
Number of subjects: 185
Study 18829392 — intervention group
Group type: EXPERIMENTAL
Intervention: MLN0002 0.5 mg/kg
Number of subjects: 185
Study 18829392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 15975977 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Duration Intermittent Hypoxia (SDIH, 12% O2 for 1 hour with 5 min normoxia)
Number of subjects: 18
Study 15975977 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-Duration Intermittent Hypoxia (LDIH, 30 min of 12% O2)
Number of subjects: 18
Study 15975977 — intervention group
Group type: COMPARATOR
Intervention: Both SDIH and LDIH
Number of subjects: 18
Study 11834958 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV2 positive at baseline
Number of subjects: 763
Study 11834958 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquiring HSV2 infection during follow‐up
Number of subjects: 763
Study 8828788 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraflo II heparin coated equipment
Number of subjects: 24
Study 8828788 — intervention group
Group type: COMPARATOR
Intervention: Uncoated equipment (control group)
Number of subjects: 24
Study 2073038 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinaceae (84 to 112 mg/day) and Sabalae (78 to 104 mg/day) extracts (URGENIN: 90 to 120 drops/day) for a mean time of 77 days
Number of subjects: 30
Study 2073038 — intervention group
Group type: COMPARATOR
Intervention: Placebo (90 to 120 drops/day) for a mean time of 52 days
Number of subjects: 30
Study 7361704 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg thiamin hydrochloride
Number of subjects: 19
Study 7361704 — intervention group
Group type: COMPARATOR
Intervention: Thiamin placebo
Number of subjects: 19
Study 30665397 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 135
Study 30665397 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity simulation
Number of subjects: 135
Study 28084062 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive elastic band resistance training for 12 weeks (3 times per week)
Number of subjects: 35
Study 28084062 — intervention group
Group type: COMPARATOR
Intervention: Control group received a 40-minute lesson about the exercise concept
Number of subjects: 35
Study 25633731 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral sentinel lymph node biopsy (LSLNB)
Number of subjects: 283
Study 25633731 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 283
Study 25543425 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog days moxibustion plaster therapy
Number of subjects: 168
Study 25543425 — intervention group
Group type: COMPARATOR
Intervention: Beclometasone dipropionate aqueous nasal spray
Number of subjects: 168
Study 20938662 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP treatment in IDO-positive DLBCL
Number of subjects: 119
Study 20938662 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP treatment in IDO-negative DLBCL
Number of subjects: 119
Study 19300380 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Steroids
Number of subjects: 178
Study 19300380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 17329690 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (9 seconds)
Number of subjects: 192
Study 17329690 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (12 seconds)
Number of subjects: 192
Study 17329690 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C (15 seconds)
Number of subjects: 192